Azienda USL Reggio Emilia - IRCCS

Quick facts

Marketed products

• Bromfenac 0.09 % Ophthalmic Solution · Ophthalmology
  Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis in the eye.
• Bromfenac eye drop · Ophthalmology
  Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis in the eye.
• Dexamethasone 0.1% ophthalmic suspension · Ophthalmology
  Dexamethasone is a potent corticosteroid that suppresses inflammatory and immune responses in the eye by binding to glucocorticoid receptors and inhibiting pro-inflammatory mediator production.
• Dexamethasone+Tobramycin eye drop · Ophthalmology
  Dexamethasone reduces inflammation and immune response while tobramycin kills bacteria, providing combined anti-inflammatory and antibiotic effects in the eye.
• Indomethacin suppository · Pain management, Rheumatology, Gastroenterology
  Indomethacin inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation, pain, and fever.

Phase 2 pipeline

• Diagnostic work up
  Diagnostic work up is not a drug but rather a clinical evaluation process to identify and characterize disease.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Azienda USL Reggio Emilia - IRCCS portfolio CI brief
• Azienda USL Reggio Emilia - IRCCS pipeline updates RSS

Frequently asked questions about Azienda USL Reggio Emilia - IRCCS

Related

• Bromfenac 0.09 % Ophthalmic Solution · Ophthalmology
• Bromfenac eye drop · Ophthalmology
• Dexamethasone 0.1% ophthalmic suspension · Ophthalmology
• Dexamethasone+Tobramycin eye drop · Ophthalmology
• Indomethacin suppository · Pain management, Rheumatology, Gastroenterology
• Sector hub: All tracked pharma companies